ライフサイエンスコーパス: salvage therapy

1 (TPE and corticosteroids, with rituximab as salvage therapy).

2 previously untreated symptomatic CLL and as salvage therapy.

3 nded by differences in the use and timing of salvage therapy.

4 have a poor prognosis with conventional-dose salvage therapy.

5 ymal stem cell transplantation may emerge as salvage therapy.

6 , 34 patients had progressed and 17 required salvage therapy.

7 tients should respond favorably to DRV-based salvage therapy.

8 and therefore have limited ability to guide salvage therapy.

9 and help to expand its applicability beyond salvage therapy.

10 nal studies are needed to define the optimal salvage therapy.

11 ors (GCT) not amenable to cure with standard salvage therapy.

12 an early stage while it is amenable to local salvage therapy.

13 eve a favorable outcome to conventional-dose salvage therapy.

14 re is critical for selecting the appropriate salvage therapy.

15 ing these men poor candidates for local-only salvage therapy.

16 d local disease, precluding successful local salvage therapy.

17 regardless of initial treatment or manner of salvage therapy.

18 Vasopressin may be considered for salvage therapy.

19 ch trials are underway to elucidate the best salvage therapy.

20 an improved clinical response to amprenavir salvage therapy.

21 for a favorable outcome to conventional-dose salvage therapy.

22 higher than the mean at weeks 2, 4, and 8 of salvage therapy.

23 rcutaneous drainage failed required surgical salvage therapy.

24 compare this approach with conventional-dose salvage therapy.

25 tional patients (16%) are currently NED with salvage therapy.

26 onal patients (19.5%) are currently NED with salvage therapy.

27 and may improve the survival of patients on salvage therapy.

28 nuously NED and three are currently NED with salvage therapy.

29 dure on the likelihood of survival following salvage therapy.

30 first remission, and two were responsive to salvage therapy.

31 icant impact on the likelihood of successful salvage therapy.

32 patient developed acute leukemia after MOPP salvage therapy.

33 red following remission underwent successful salvage therapy.

34 were being considered for curative-intent or salvage therapy.

35 has become the key factor for the choice of salvage therapy.

36 urrence is of high importance for successful salvage therapy.

37 were being considered for curative-intent or salvage therapy.

38 IMC who underwent FMT from healthy donors as salvage therapy.

39 fter radical prostatectomy, and prior to any salvage therapy.

40 rounding HDM-AHCT use as both front-line and salvage therapy.

41 splantation or who fail induction therapy or salvage therapy.

42 f 9 with other first-line treatment received salvage therapy.

43 olvement at the start of pre-transplantation salvage therapy.

44 performed after completion of definitive or salvage therapy.

45 e potentially treated with multiple lines of salvage therapy.

46 metastases (DMs), PSA failure, and rates of salvage therapy.

47 n of intravitreal bevacizumab as primary and salvage therapy.

48 tors in visual acuity (VA) after proton beam salvage therapy.

49 nce population treated with standard-of-care salvage therapy.

50 ble patients with relapsed DLBCL in PR after salvage therapy.

51 se, biochemical recurrence, or initiation of salvage therapy.

52 se/persistence of infection, or the need for salvage therapy.

53 neck dissection was a result of less use of salvage therapy.

54 nt (HCT) who subsequently received ibrutinib salvage therapy.

55 from steroid-refractory acute GvHD with MSC salvage therapy.

56 cer and may facilitate earlier initiation of salvage therapy.

57 hese patients can be cured with conventional salvage therapy.

58 gh risk for recurrence and in candidates for salvage therapy.

59 the follow-up of PCa patients for tailoring salvage therapy.

60 dation extends time to progression requiring salvage therapy.

61 gly challenging largely due to resistance to salvage therapy.

62 r outcome was not influenced by the proposed salvage therapy.

63 lure of auto-SCT and in partial responses to salvage therapy.

64 s (75%), were administered before IMiD-based salvage therapy.

65 llow the response of patients to adjuvant or salvage therapies.

66 fy prostate cryoablation as both primary and salvage therapies.

67 ed its recommendations on both frontline and salvage therapies.

68 ay improve the efficacy of genotype-assisted salvage therapies.

69 poor prognoses, due to the lack of effective salvage therapies.

70 oor, with a need for alternatives to current salvage therapies.

71 These findings might be used to select salvage therapies.

72 despite substantial use of novel-agent-based salvage therapies.

73 ); however, they were more likely to receive salvage therapy (27.8% v 9.1%, P < .001).

74 ACVBP (54% vs 41%; P = .08), leading to more salvage therapy (37% vs 26%; P = .07) and lower event-fr

75 refractory disease fare worse (CR rate with salvage therapy, 7%; median OS, 6 months).

76 e that were CD38-positive had a mean time to salvage therapy 71 months shorter than patients who were

77 The 138 patients started CAZ-AVI salvage therapy after a first-line treatment (median, 7

78 study was to evaluate the efficacy of SVV as salvage therapy after at least one course of DAA.

79 into the paracolic gutters and pelvis or for salvage therapy after endoscopic or surgical debridement

80 dioembolization with (90)Y microspheres as a salvage therapy after failed PRRT.

81 ory coccidioidomycosis were treated with V/C salvage therapy after failing conventional therapy consi

82 Salvage therapy after recurrence increased with margin w

83 8 hrs; and 2) HBOC-201 could be an effective salvage therapy after severe neurotrauma or as a tempori

84 ing that NLS-targeting agents would serve as salvage therapy agents for highly INSTI-resistant varian

85 investigate the prevalence and influence of salvage therapy among patients with recurrent disease.

86 Hence, there is a need to develop effective salvage therapies and combine novel agents with standard

87 lengths of stay, but are at higher risk for salvage therapy and anastomotic strictures.

88 d were rendered continuously disease-free by salvage therapy and are alive.

89 cHL are being tested as part of primary and salvage therapy and are also highly relevant for HIV-cHL

90 ssion analysis, response to cytoreductive or salvage therapy and B symptoms at relapse were the most

91 s may thus be best strategically used before salvage therapy and before significant CD4 + T cell depl

92 , carboplatin, and etoposide (NICE) as first salvage therapy and bridge to autologous hematopoietic c

93 resilient T cells in patients rebound after salvage therapy and ME1 enhances their resiliency.

94 ly a fraction of patients will be cured with salvage therapy and transplantation.

95 ging from 0.2 to 2.0 ng/mL without any prior salvage therapy and with a Karnofsky performance status

96 tors and mycophenolate mofetil are potential salvage therapies, and reagents such as recombinant inte

97 d as PSA nadir plus 2 ng/mL or initiation of salvage therapies, and the Fine and Gray competing risks

98 ails may have a response to and benefit from salvage therapies, and their prognosis is relatively goo

99 assive bleeding with poor visualization, for salvage therapy, and for diffuse bleeding from malignanc

100 ins disease free more than 6 years following salvage therapy, and one unexpected death occurred.

101 py with rituximab appears to be effective as salvage therapy, and ongoing clinical trials should dete

102 er, many of these children responded well to salvage therapy, and overall survival rates did not diff

103 adical prostatectomy, and prior to potential salvage therapy, and results in a potential change in tr

104 igh frequency of relapse, poorer response to salvage therapy, and shorter overall survival than those

105 to recommendations for staging, initial and salvage therapy, and surveillance.

106 rrence for soft tissue sarcomas, the role of salvage therapy, and the data in support of current surv

107 zed this group of patients for risk factors, salvage therapy, and treatment outcome.

108 e and its clonality is required to implement salvage therapies appropriately.

109 relapse and survival status, and results of salvage therapy are reported.

110 eatment FDG PET performed during primary and salvage therapy are reviewed and management strategies c

111 hted or weighted drug-specific GSSs for each salvage therapy ARV.

112 nhibitors (NRTIs) can be safely omitted from salvage therapy as long as the regimen has a cumulative

113 d of cytotoxic CD8(+) T cells in response to salvage therapy as T cell resilience and examined the un

114 ed isavuconazole for >=24 h as first-line or salvage therapy at 10 Spanish centers between September

115 l patients received proton beam therapy as a salvage therapy at the Helmholtz Zentrum Berlin between

116 In the absence of salvage therapy, at least three quarters of men will hav

117 vincristine, and prednisone plus second-line salvage therapy +/- autologous stem-cell transplant).

118 rategy 2: polatuzumab-R-CHP plus second-line salvage therapy +/- autologous stem-cell transplant; str

119 eral concept of RIST with intensive standard salvage therapy before alloHCT for all patients, because

120 cell cancer unlikely to be cured by standard salvage therapy but without proven refractoriness to che

121 ogress, perhaps partly due to more effective salvage therapies, but the FFS data also indicate improv

122 radiation therapy (SIRT) has been tested as salvage therapy, but no data exist about its use as firs

123 a form of drug provocation testing, helps to salvage therapy by identifying culprit drugs but is asso

124 should optimize efficacy and tolerability of salvage therapy by stratifying patients according to ris

125 HIV-1 salvage therapy can safely omit NRTIs without compromisi

126 in the Obs arm received IFNalpha-containing salvage therapy compared with the HDI arm; this therapy

127 and the search for more effective and tissue-salvaging therapies continues.

128 cer treatment, the availability of effective salvage therapies could make definitive phase III trials

129 efine sites of disease recurrence and inform salvage therapy decisions than does conventional imaging

130 ence at the resection margin, and chance for salvage therapy, defined as complete eradication of recu

131 kov model to simulate primary, adjuvant, and salvage therapy; disease recurrence; and survival in pat

132 rogression, local failure, regional failure, salvage therapy, distant metastasis, prostate cancer-spe

133 juvant radiotherapy as compared with delayed salvage therapy do not exist.

134 vuconazole was used as first-line (72.8%) or salvage therapy due because of previous treatment-emerge

135 had new metastatic disease or initiation of salvage therapy during follow-up.

136 Salvage therapies empirically conducted with 50 (n = 4),

137 Liver transplantation is an effective salvage therapy, even in the elderly, and AIH must be co

138 matologic malignancies for whom standard and salvage therapies failed were treated with LMB-2 at dose

139 nd is emerging as the most frequent cause of salvage therapy failure.

140 Effective salvage therapy followed the recognition of some of the

141 undred fourteen patients received subsequent salvage therapy following KI discontinuation with an ORR

142 rane oxygenation within the context of other salvage therapies for acute respiratory failure.

143 The assessment of new front-line and salvage therapies for adults and children were given top

144 kers of heterogeneous treatment response and salvage therapies for CRPC patients.

145 at 300 to 1000 mg per day and was the first salvage therapy for 47 patients.

146 The salvage therapy for a local recurrence after successful

147 n elderly patients with comorbidities and as salvage therapy for achalasia.

148 domide is an immunomodulatory drug active as salvage therapy for chronic lymphocytic leukemia (CLL).

149 status was associated with a shorter time to salvage therapy for disease progression (P < .001), perh

150 Salvage therapy for disseminated germ cell tumors of all

151 TI-CE is effective salvage therapy for GCT patients with poor prognostic fe

152 CT) have widened its use as consolidation or salvage therapy for high-risk hematological malignancies

153 nazole, a new extended-spectrum triazole, as salvage therapy for IFIs in SOT recipients.

154 y of whole-brain radiation therapy (WBRT) as salvage therapy for immunocompetent patients who failed

155 zobactam-ceftazidime-avibactam may represent salvage therapy for individuals with CF and highly drug-

156 l evaluated scenarios, SBRT was preferred as salvage therapy for local progression after RFA.

157 However, SBRT is the preferred salvage therapy for local progression after RFA.

158 lication of ICECaP-1 and evaluating adjuvant/salvage therapy for localized PCa, and which collected M

159 th weekly (days eight and 15) vinorelbine as salvage therapy for metastatic breast cancer in anthracy

160 single-agent intravenous (IV) vinorelbine as salvage therapy for metastatic breast cancer.

161 emozolomide + irinotecan is commonly used as salvage therapy for neuroblastoma.

162 Using phages as salvage therapy for nonhealing infections is gaining rec

163 idance about which therapy should be used as salvage therapy for patients after failure of a first-li

164 These results suggest an effective salvage therapy for patients for whom direct-acting anti

165 One potential use for amprenavir is as salvage therapy for patients for whom treatment that inc

166 ination with immunosuppressive agents, or as salvage therapy for patients who do not respond or lose

167 nical trials, SVV proved highly effective as salvage therapy for patients who failed a previous DAA t

168 An analysis of salvage therapy for patients who relapsed on E1690 demon

169 is an integral part of consolidation and/or salvage therapy for patients with acute myeloid leukemia

170 hen R was included in the pretransplantation salvage therapy for patients with intermediate-grade NHL

171 Salvage therapy for patients with RP was delivered a med

172 efit of targeted reinforcement could improve salvage therapy for progressive neuroblastoma.

173 Salvage therapy for progressive or recurrent primary cen

174 VEGF blockade is still widely used as salvage therapy for recurrent GBM, therefore these intri

175 mbination voriconazole and caspofungin (V/C) salvage therapy for refractory coccidioidomycosis at two

176 ons are warranted to support the role of V/C salvage therapy for refractory coccidioidomycosis.

177 Their depletion has been proposed as salvage therapy for refractory disease.

178 ere estimated from the time of initiation of salvage therapy for refractory disease.

179 Conventional salvage therapy for relapsed follicular or low-grade lym

180 (50%) are alive, 6 in continuous CR, 2 after salvage therapy for relapsed or refractory disease, and

181 e needed to confirm the potential of MSCs as salvage therapy for steroid-refractory GvHD and to ident

182 usions (DLI) has been proven to be effective salvage therapy for the majority of patients who relapse

183 Injectable ARVs can provide salvage therapy for those with limited therapeutic optio

184 R, 43 IR MRD-positive) plus 23 rescued after salvage therapy, for a total of 188 candidates; 150 (44%

185 alovirus (CMV) infection is challenging, and salvage therapies, foscarnet, and cidofovir, have signif

186 ponsive to conventional rituximab-containing salvage therapy from 12 oncology-haematology centres in

187 (complete response [CR] rates with standard salvage therapy gemcitabine plus oxaliplatin [GemOx], ~3

188 ond to or who have progressive disease after salvage therapies have a poor prognosis.

189 ts is monthly observation with initiation of salvage therapy if and when there is serologic progressi

190 ort the use of autologous transplantation as salvage therapy if such patients achieve a subsequent CR

191 jury in pediatric and adult patients, and as salvage therapy in adult patients with acute respiratory

192 The role of salvage therapy in advanced disease remains undefined.

193 vide a substantial initial efficacy rate for salvage therapy in heavily antiretroviral-experienced HI

194 Pixantrone, given as a single-agent salvage therapy in heavily pretreated patients with rela

195 TIPS is highly effective as salvage therapy in high-risk patients with active varice

196 EN/AZA therapy represents a novel and active salvage therapy in patients who had relapsed post-allogr

197 nt or with a variety of FU-based regimens as salvage therapy in patients with advanced colorectal can

198 red in combination were evaluated as initial salvage therapy in patients with relapsed or refractory

199 (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/

200 ailable data also support a limited role for salvage therapy in the setting of isolated local recurre

201 Risk factors for needing salvage therapy included reduced pulmonary diffusing cap

202 Patients with relapsed lymphomas often fail salvage therapies including high-dose chemotherapy and m

203 The optimal pre-salvage therapy investigational workup for patients who

204 refore, the optimal candidate for local-only salvage therapy is a man whose pretreatment PSA velocity

205 d C-reactive protein > 45 mg/l on day 3) and salvage therapy is appropriate at this stage.

206 therapy to assess for recurrence and to plan salvage therapy is described.

207 cific antigen (PSA) levels at which targeted salvage therapy is effective.

208 icians to recognize that the primary goal of salvage therapy is to maximize disease-free survival and

209 5 years achieved a CR with either initial or salvage therapy; limited data suggest the same for patie

210 Single-drug maintenance after salvage therapy might be an attractive strategy to prolo

211 use in 2014 and now is used for initial and salvage therapy of CLL patients.

212 neration HIV-1 fusion inhibitor approved for salvage therapy of HIV-1-infected patients refractory to

213 -label trial that studied primary as well as salvage therapy of invasive mucormycosis showed efficacy

214 axel did not result in improved survival for salvage therapy of patients with advanced-stage lung ade

215 therapy cycle on arm C and, if necessary, as salvage therapy on all three treatment arms.

216 BCG-unresponsive disease have few effective salvage therapy options besides radical cystectomy, high

217 rty-five percent of patients did not require salvage therapies or colectomy during the first year pos

218 eatment challenge, as they do not respond to salvage therapy or allogeneic stem cell transplant.

219 T], or no response to or relapse after first salvage therapy or beyond) leukaemia.

220 been in heterogeneous patient groups needing salvage therapy or presenting at varied time points.

221 es (OR, 0.93; 95% CI, 0.87 to 0.99) and less salvage therapy (OR, 0.92; 95% CI, 0.88 to 0.98).

222 0; 95% CI, 1.04 to 1.87) and higher rates of salvage therapy (OR, 3.67; 95% CI, 2.81 to 4.81).

223 fection persistence/relapse, death, need for salvage therapy, or prosthesis removal occurred.

224 lyzed for the frequency of LRF over time and salvage therapy outcomes.

225 ho underwent allogeneic or autologous SCT as salvage therapy (P = .019).

226 ese situations, its use should be limited to salvage therapy pending the publication of controlled tr

227 -nine (94%) patients had cHL and 27 had >/=1 salvage therapy post-allo-HCT and prior to anti-PD-1 tre

228 Daratumumab salvage therapy produced good results and remission rate

229 ization, complications, lengths of stay, and salvage therapy rates for MIRP versus open radical prost

230 had a short survival period, irrespective of salvage therapy received; these patients have high unmet

231 as to investigate the effect of initiating a salvage-therapy regimen on resistant viruses in heavily

232 at baseline and at weeks 2, 4, and 8 of the salvage-therapy regimen.

233 se inhibitors may represent a potent drug in salvage therapy regimens after failure of an indinavir o

234 dy compared antiretroviral activity among 6 "salvage" therapy regimens.

235 Rational design of salvage therapies requires new methods to assess drug su

236 treatment-related mortality associated with salvage therapies, response rates of salvage regimens, a

237 Salvage therapy SCID-X1 patients over 2 years old (NCT01

238 le investigating the off-label use of BDQ as salvage therapy, seven of 13 patients with Mycobacterium

239 fosfamide, carboplatin, and etoposide)-based salvage therapy (ST) proceeded to high-dose chemoradioth

240 s of tumor-derived DNA in Rb eyes undergoing salvage therapy that have not been enucleated.

241 Mycophenolate mofetil is a possible salvage therapy that requires clinical trial, and liver

242 atients undergoing primary site resection as salvage therapy, the overall local control rate is 92.4%

243 Originally intended for life-saving salvage therapy, the use of temporary mechanical circula

244 darabine, cyclophosphamide, and rituximab as salvage therapy, there was no significant improvement in

245 lymphocyte infusions (DLIs) can be effective salvage therapy they are associated with severe graft-ve

246 ic myeloid leukaemia, representing an active salvage therapy to bridge to allogeneic HSCT.

247 uired to undergo a minimum of two courses of salvage therapy to determine chemosensitivity before tra

248 T]) is to implement a potentially beneficial salvage therapy to overcome possible morbidity/mortality

249 In patients with DLBCL in a PR after salvage therapy, treatment with auto-HCT was associated

250 25; P <.001), PCSM (HR, 0.10; P = .007), and salvage therapy use (HR, 0.62; P = .025).

251 mor, 18 (53%) were successfully treated with salvage therapy via cystectomy, and 16 patients (16%) di

252 he 10-year actuarial survival rate following salvage therapy was 65% overall, 65% for patients in who

253 Salvage therapy was successful with second-line chemothe

254 The aim of salvage therapy was to achieve a complete remission (CR)

255 ents with HR-NB who achieved remission after salvage therapies were enrolled in this trial.

256 Salvage therapies were used more frequently after OBS th

257 , and favorable response to cytoreductive or salvage therapy were most predictive of superior FFP and

258 c features for response to conventional-dose salvage therapy were treated.

259 Factors predicting a good outcome after salvage therapy were young age (OS of 12% in patients yo

260 red for mixed chimerism and their utility as salvage therapy when given for relapse.

261 Optimal salvage therapy will depend on detailed results of rando

262 f positron emission tomography (PET)-adapted salvage therapy with brentuximab vedotin (BV) and augmen

263 PET-adapted sequential salvage therapy with brentuximab vedotin followed by aug

264 the feasibility and activity of PET-adapted salvage therapy with brentuximab vedotin, followed by au

265 Salvage therapy with chemotherapy or targeted therapy is

266 n, and chemotherapy were used as postrelapse salvage therapy with greatest frequency, yet high variab

267 Salvage therapy with ibrutinib after VenR achieved high

268 leic acids in the AH from Rb eyes undergoing salvage therapy with intravitreous injection of melphala

269 PET-adapted sequential salvage therapy with nivolumab/nivolumab+NICE was well t

270 es in similarly selected patients undergoing salvage therapy with one or two cycles of chemotherapy c

271 Here we report salvage therapy with ursodeoxycholic acid (UDCA) to prev

272 -cell non-Hodgkin lymphoma chemosensitive to salvage therapy with: (1) positron emission tomography-p

273 nd five of them remain free of disease after salvage therapy, with a median follow-up period of 79 mo